{
    "id": 16300,
    "fullName": "IGF1R positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "IGF1R positive indicates the presence of the IGF1R gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 3480,
        "geneSymbol": "IGF1R",
        "terms": [
            "IGF1R",
            "CD221",
            "IGFIR",
            "IGFR",
            "JTK13"
        ]
    },
    "variant": "positive",
    "createDate": "01/12/2016",
    "updateDate": "04/25/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 4596,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KW-2450 treatment inhibited Igf1r signaling and resulted in moderate tumor growth inhibition in a colon carcinoma xenograft model (PMID: 26850678).",
            "molecularProfile": {
                "id": 16581,
                "profileName": "IGF1R positive"
            },
            "therapy": {
                "id": 785,
                "therapyName": "KW-2450",
                "synonyms": null
            },
            "indication": {
                "id": 1520,
                "name": "colon carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4624,
                    "pubMedId": 26850678,
                    "title": "Preclinical and first-in-human phase I studies of KW-2450, an oral tyrosine kinase inhibitor with insulin-like growth factor receptor-1/insulin receptor selectivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26850678"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8595,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BLZ945 treatment resulted in minimal survival of transgenic glioblastoma mouse models expressing IGF1R (PMID: 27199435).",
            "molecularProfile": {
                "id": 16581,
                "profileName": "IGF1R positive"
            },
            "therapy": {
                "id": 2844,
                "therapyName": "BLZ945",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6692,
                    "pubMedId": 27199435,
                    "title": "The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27199435"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8593,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, glioblastoma transgenic mouse models expressing IGF1R demonstrated minimal survival when treated with Linsitinib (OSI-906) alone (PMID: 27199435).",
            "molecularProfile": {
                "id": 16581,
                "profileName": "IGF1R positive"
            },
            "therapy": {
                "id": 798,
                "therapyName": "Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6692,
                    "pubMedId": 27199435,
                    "title": "The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27199435"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8550,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cometriq (cabozantinib) inhibited Abiraterone-induced Igf1r activation, resulted in enhanced growth inhibition in prostate cancer cell lines in culture and in cell line xenograft models (PMID: 26289068).",
            "molecularProfile": {
                "id": 16581,
                "profileName": "IGF1R positive"
            },
            "therapy": {
                "id": 4770,
                "therapyName": "Abiraterone + Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6685,
                    "pubMedId": 26289068,
                    "title": "Cabozantinib Inhibits Abiraterone's Upregulation of IGFIR Phosphorylation and Enhances Its Anti-Prostate Cancer Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26289068"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4591,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KW-2450 treatment in multiple human malignant cell lines inhibited Igf1r activity and cell growth (PMID: 26850678).",
            "molecularProfile": {
                "id": 16581,
                "profileName": "IGF1R positive"
            },
            "therapy": {
                "id": 785,
                "therapyName": "KW-2450",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4624,
                    "pubMedId": 26850678,
                    "title": "Preclinical and first-in-human phase I studies of KW-2450, an oral tyrosine kinase inhibitor with insulin-like growth factor receptor-1/insulin receptor selectivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26850678"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9235,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alunbrig (brigatinib) inhibited growth of liver cancer cells with activated Igf1r signaling via Igf stimulation in culture (PMID: 27780853).",
            "molecularProfile": {
                "id": 16581,
                "profileName": "IGF1R positive"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3571,
                "name": "liver cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7044,
                    "pubMedId": 27780853,
                    "title": "The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27780853"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8591,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Linsitinib (OSI-906) and BLZ945 compared to BLZ945 alone resulted in a greater survival benefit, decreased cell proliferation, and tumor regression in transgenic mouse models of glioblastoma expressing IGF1R (PMID: 27199435).",
            "molecularProfile": {
                "id": 16581,
                "profileName": "IGF1R positive"
            },
            "therapy": {
                "id": 4773,
                "therapyName": "BLZ945 + Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6692,
                    "pubMedId": 27199435,
                    "title": "The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27199435"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6871,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Tarceva (erlotinib) and Linsitinib (OSI-906) combination treatment decreased Igf1r and Insr phosphorylation, resulted in a disease control rate of 51% (38/75), and partial response in 7% (5/75) of patients with advanced solid tumors, including a rectal cancer patient who remained on study for 36 weeks (PMID: 26831715).",
            "molecularProfile": {
                "id": 23919,
                "profileName": "IGF1R pos INSR pos"
            },
            "therapy": {
                "id": 4041,
                "therapyName": "Erlotinib + Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1993,
                "name": "rectum cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5935,
                    "pubMedId": 26831715,
                    "title": "Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26831715"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6872,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Tarceva (erlotinib) and Linsitinib (OSI-906) combination treatment decreased Igf1r and Insr phosphorylation, resulted in a disease control rate of 51% (38/75), and partial response in 7% (5/75) of patients with advanced solid tumors, including three non-small cell lung carcinoma patients who remained on study for 16, 72, 36 weeks, respectively (PMID: 26831715).",
            "molecularProfile": {
                "id": 23919,
                "profileName": "IGF1R pos INSR pos"
            },
            "therapy": {
                "id": 4041,
                "therapyName": "Erlotinib + Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5935,
                    "pubMedId": 26831715,
                    "title": "Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26831715"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6870,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Tarceva (erlotinib) and Linsitinib (OSI-906) combination treatment decreased Igf1r and Insr phosphorylation, resulted in a disease control rate of 51% (38/75), and partial response in 7% (5/75) of patients with advanced solid tumors, including a spinal chordoma patient who remained on study for more than 268 weeks (PMID: 26831715).",
            "molecularProfile": {
                "id": 23919,
                "profileName": "IGF1R pos INSR pos"
            },
            "therapy": {
                "id": 4041,
                "therapyName": "Erlotinib + Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 4153,
                "name": "spinal chordoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5935,
                    "pubMedId": 26831715,
                    "title": "Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26831715"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6869,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Tarceva (erlotinib) and Linsitinib (OSI-906) combination treatment decreased Igf1r and Insr phosphorylation, resulted in partial response in 7% (5/75), and a disease control rate of 51% (38/75) in patients with advanced solid tumors (PMID: 26831715).",
            "molecularProfile": {
                "id": 23919,
                "profileName": "IGF1R pos INSR pos"
            },
            "therapy": {
                "id": 4041,
                "therapyName": "Erlotinib + Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5935,
                    "pubMedId": 26831715,
                    "title": "Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26831715"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9577,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Linsitinib (OSI-906) in combination with Iressa (gefitinib) and PHA-665752 decreased proliferation of lung adenocarcinoma cell lines harboring EGFR E746_A750del and MET amplification, with acquired resistance to Iressa (gefitinib) and PHA-665752 combination therapy due to activation of IGF1R signaling (PMID: 27612490).",
            "molecularProfile": {
                "id": 26907,
                "profileName": "EGFR E746_A750del IGF1R pos MET amp"
            },
            "therapy": {
                "id": 5095,
                "therapyName": "Gefitinib + Linsitinib + PHA-665752",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7271,
                    "pubMedId": 27612490,
                    "title": "Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27612490"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9574,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung adenocarcinoma cell lines harboring EGFR E746_A750del and MET amplification acquired resistance to treatment with the combination of Iressa (gefitinib) and PHA-665752 due to bypass activation of IGF1R in culture (PMID: 27612490).",
            "molecularProfile": {
                "id": 26907,
                "profileName": "EGFR E746_A750del IGF1R pos MET amp"
            },
            "therapy": {
                "id": 5094,
                "therapyName": "Gefitinib + PHA-665752",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 7271,
                    "pubMedId": 27612490,
                    "title": "Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27612490"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9579,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of BI 836845 and PHA-665752 inhibited AKT and ERK signaling and induced apoptosis in lung adenocarcinoma cell lines harboring EGFR E746_A750del and MET amplification with acquired resistance to Iressa (geftinib) and PHA-665752 combination therapy due to activation of IGF1R signaling (PMID: 27612490).",
            "molecularProfile": {
                "id": 26907,
                "profileName": "EGFR E746_A750del IGF1R pos MET amp"
            },
            "therapy": {
                "id": 5096,
                "therapyName": "PHA-665752 + Xentuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7271,
                    "pubMedId": 27612490,
                    "title": "Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27612490"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 16581,
            "profileName": "IGF1R positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23919,
            "profileName": "IGF1R pos INSR pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26243,
            "profileName": "IGF1R pos PIK3CA pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26907,
            "profileName": "EGFR E746_A750del IGF1R pos MET amp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}